“AZ Vaccine-No Thrombosis Causality…2 Severe Abnormalities Related”

The vaccination committee recommended that the vaccine continue to be vaccinated, saying it is difficult to say that a blood clot was formed due to the AstraZeneca vaccine. However, for the other two adverse reactions, the causality with the vaccine was recognized for the first time.

This is reporter Kim Hyung-rae.

<기자>

First of all, the Vaccination Committee said that thrombosis, which causes blood in the blood vessels to harden, is a relatively common disease.

Most of them are in bedridden patients, as well as in patients with infections or cancer, but a review of domestic and foreign cases revealed no association that vaccination increased the risk of blood clots.

[최은화/예방접종전문위원회 위원장 : 아스트라제네카 백신 접종 후 관찰된 혈전 생성 사례는 평상시 발생 수준보다 더 낮은 것으로 보고됐습니다.]

It is the same as the conclusion of the World Health Organization and the European Medicines Agency, except that cerebral sinus thrombosis that occurred in men in their twenties in Korea should be investigated further for its causality with the vaccine.

This disease is very rare, with a blood clot blocking the blood vessels in the brain, and unlike general thrombosis, there are 13 per million people.

[나상훈/서울대병원 순환기내과 교수 : 마치 망치로 머리를 때리는 것 같은, 평생 한 번도 경험하지 못한 심한 통증이 있고 시야가 흐려지는 증상 등이 보고될 수 있습니다.]

Health officials also acknowledged the causality of the vaccine for two serious adverse reactions after vaccination with AstraZeneca.

This is a case in the 20s who showed anaphylaxis, an acute allergic reaction 7 minutes after vaccination, and in their 40s, where blood pressure fell the next day following convulsions and high fever half a day after vaccination.

Both of them are now feeling better.

This is the first time that our health authorities have recognized the connection between COVID-19 vaccination and adverse reactions.

In this way, if the causality with the vaccine is recognized, you can apply for compensation for damage and receive compensation for medical expenses, etc., according to the deliberation of the expert committee.

.Source